Cepheid

Sunnyvale, United States Founded: 1996 • Age: 30 yrs Listed Acquired By Danaher
Developer of molecular diagnostic testing solutions

About Cepheid

Cepheid is a Healthcare company based in Sunnyvale (United States) founded in 1996, and was acquired by Danaher in September 2016. It operates as a developer of molecular diagnostic testing solutions. Cepheid has raised $19.1 million across 8 funding rounds from investors including Medtronic, NIH and Danaher. The company has 208 employees. Cepheid has completed 1 acquisition, including OncoMark. Its website cepheid.com draws about 118 thousand monthly visits. Its Indian entity Cepheid India Private Limited reported revenue of ₹720 Cr. Its focus areas include Life Sciences, Genomics, Enabling Technologies and Instrument Systems. Its competitors include Beckman Coulter, Blackrock Neurotech, Bruker, Complete Genomics and Esco Lifesciences and 4 more; 5 of its 9 listed competitors have raised funding.

Company details

Cepheid was founded in 1996 in Sunnyvale, United States, within the molecular diagnostics sector. Testing solutions are provided across categories including hospital-acquired infections, critical infectious diseases such as multi-drug resistant tuberculosis, influenza, respiratory syncytial virus, and enteroviral meningitis, as well as sexual health and genetic assessments like a 30-minute test for thrombosis risk. Operations focus on healthcare applications in the United States.

  • Headquarters Sunnyvale, United States
  • Employees 208
  • Stage Acquired
  • Sectors
    Healthcare
  • Website category Health · Biotechnology and Pharmaceuticals
  • Website cepheid.com
  • Social LinkedIn X YouTube
  • Acquired by Danaher (Sep 2016)
  • Legal Name Cepheid India Private Limited
  • Date of Incorporation 22 Aug, 2013
  • Jurisdiction Gurugram, Haryana, India
Key Metrics
  • Annual Revenue
    ₹720 Cr

    FY 2025 · +29% YoY

  • Net Profit
    ₹21.69 Cr

    FY 2025 · 3% margin

  • EBITDA
    ₹55.88 Cr

    FY 2025 · 8% margin

  • Total Equity Funding
    $19.1M (USD)

    in 8 rounds

  • Latest Funding Round
    $28M (USD), Grant

    Jul 2021

  • Investors
    Medtronic

    & 11 more

  • Employee Count
    208
  • Investments & Acquisitions
  • Acquired by
    Danaher

    (Sep 2016)

Apps and channels of Cepheid

its YouTube channel Cepheid has 6.57K subscribers and 30 videos.

Cepheid
YouTube 6.57K subscribers 30 videos Nonprofits & Activism
Open channel

Videos from Cepheid

The most watched videos on Cepheid's YouTube channel, Cepheid (6.57K subscribers). Click a video to play it here.

With High Levels of Interseasonal Flu, We Need to do More
14.9K views
The Benefit of PCR to Pinpoint What Respiratory Viruses People Have
8.9K views
The Savings are Potentially Enormous with Fast PCR Testing
7.9K views
Intrapartum GBS Testing: The point-of-view of the Neonatologist
6.2K views

More on Cepheid.

Funding Insights of Cepheid

Cepheid has successfully raised a total of $19.1M across 8 strategic funding rounds. The most recent funding activity was a Grant round of $28 million completed in July 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $19.1M
  • Total Rounds 8
  • Last Round Grant — $28M
  • First Round $19.1M

    (Jan 2000)

  • Investors Count 11

All 8 funding rounds of Cepheid with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Jul 2021$28MGrant––
Jan 2013$5.2MPost-IPO––
–
Jun 2012$19,926Grant––
Aug 2008$1.16MGrant––
Aug 2002$376,000Grant––
Aug 2002$1.16MGrant––
May 2000–Grant––
Jan 2000$19.1MSeries C––
Valuation history

12 investors in total: 12 institutional.

Investors in Cepheid

Cepheid has secured backing from 12 investors, including institutional and venture fund investors. Prominent investors backing the company include Medtronic, NIH and Danaher.

All
Venture Fund
Institutional
InvestorDescriptionFounded YearDomainLocation
Tech-based companies are invested in by Wheatley Partners.
–wheatleypartners.comGreat Neck, United States
Biotechnology investments are targeted by the venture capital firm.
–merlinbiomed.comNew York, United States
PE firm investing in the US
–rhcapco.comSan Francisco, United States
VC firm making investment in early stage startups in the US
–atvcapital.comMenlo Park, United States
BARDA is focused on developing medical countermeasures for public health security.
–medicalcountermeasures.govUnited States
Drug discovery services are provided to the biopharma sector.
1887nih.govUnited States
Public health and human services are overseen by HHS.
1953hhs.gov-
-
1958darpa.milUnited States
Investment firm offering equity and hedge funds to accredited investors worldwide.
1960formulagrowth.comNew York, United States
Medical equipment for treating over 30 chronic diseases is developed.
1949medtronic.comMinneapolis, United States
Premium access

Investor details for Cepheid

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Board of directors of Cepheid India Private Limited (Cepheid)

Cepheid India Private Limited is the primary company behind Cepheid. The board of Cepheid India Private Limited currently have 3 directors; the longest-serving is Ganesh S Iyer, appointed in 2020. 13 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Ganesh S Iyer
DIN 02611796
Director27 Mar 20206 yrs 6 moCepheid India Private Limited
Dhiraj Sood
DIN 07945660
Director28 Jul 20224 yrs 2 moCepheid India Private Limited
Santosh Kumar Nandi Duli
DIN 10780872
Director24 Sep 20242 yrsCepheid India Private Limited

People of Cepheid

662 people are tracked at Cepheid (213 in leadership, 449 in team); the tracked headcount is 208.

NameRoleGroup
Dean Henderson
Global Purchasing DirectorLeadership
Kim Gilonske
Vice President, Commercial SolutionsLeadership
Patrick H.
Vice President, Global StrategyLeadership
Irene Domingo
Director, Commercial HRLeadership
Luben Li
Senior Vice President, Marketing & Product ManagementLeadership
Tamanna Prashar
Vice President, Global Supply ChainLeadership
Murali Palaniappan
Vp, Software Engineering, R&dLeadership
John Bishop
Chairman & CEOLeadership
Rachel McCrackan
Director, HR Business Partner (r&d)Leadership
Uma Krishnan
Director Architecture Digital TransformationLeadership
Kalyani Mangipudi
DirectorLeadership
Farangiz Mirzoeva
Director, Medical And Scientific AffairsLeadership
Gerda S.
Vice President Human ResourcesLeadership
Christine Box
Senior Director Human Resources EMEALeadership
Beth McCarthy
Sr. Human Resources Business PartnerLeadership
Yash Jani
Sr. Director, Government ProgramsLeadership
Cristina Baker M.D.
Senior Director Medical AffairsLeadership
Mona Zaccheus
Director Supply PlanningLeadership
Traci Wicks
Senior Vice President, Cepheid Human Resources And Internal Communications LeaderLeadership
Will Lee
Director Customer Defect Tracking And ResolutionLeadership

642 more people are available in the full profile.

Premium access

Complete people profiles for Cepheid

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Financials of Cepheid

Figures of Cepheid India Private Limited, the primary company behind Cepheid, for FY 2025. Revenue was ₹720 Cr (+29% year on year). Net profit was ₹21.69 Cr (3% margin). EBITDA was ₹55.88 Cr (8% margin). Revenue has grown at a compounded annual rate of +17% over three years and +10% over five years.

  • ₹720 CrRevenue · FY 2025 · +29% YoY
  • ₹21.69 CrNet profit · 3% margin
  • ₹55.88 CrEBITDA · 8% margin
  • ₹1.1 LakhPaid-up capital
  • 208Employees (provident fund records)
  • +17%Revenue CAGR, 3 years
  • +10%Revenue CAGR, 5 years

Balance sheet, profit and loss, cash flow and ratios of Cepheid India Private Limited are on its company page.

Premium access

Detailed financial statements for Cepheid

Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.

  • Statement rows
  • Financial ratios
  • Five-year trends
  • Downloads

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Cepheid

Cepheid has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include OncoMark.

Acquisitions
Company NameDescriptionDomainLocationFoundedAcquiredAmount
Tissue-based cancer diagnostics are developed by OncoMark.
oncomark.comDublin, Ireland2011Dec 2021••••
Premium access

Complete acquisition details for Cepheid

Acquired stakes, deal sources and the complete acquisition history require an active premium plan.

  • Acquired stakes
  • Deal sources
  • Complete history
  • Exports

Verified entity values are shown only after access is granted.

Timeline of Cepheid

6 dated milestones of Cepheid across 25 years, from founding to its latest funding, stage changes and deals.

  1. Founded Cepheid is founded.
  2. Funding First funding round of $19.1M.
  3. IPO Lists on the stock exchange (IPO).
  4. Exit Acquired by Danaher.
  5. Funding Latest funding round, Grant, of $28.0M.
  6. Acquisition Acquires OncoMark.

Competitors of Cepheid

Cepheid has 9 listed competitors in our database, 5 of them funded. They include Beckman Coulter, Blackrock Neurotech, Bruker, Complete Genomics and Esco Lifesciences, among others.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
beckman.com1935Brea, United States––
Provider of products for biomedical testing for R&D, diagnostic and commercial applications
blackrockneurotech.com2008Salt Lake, United States$22.37M127
Medical devices for neurological therapies are developed.
bruker.com1960United States–9,707
Diversified research instrument systems are manufactured and supplied.
completegenomics.com2006San Jose, United States$124.99M70
DNA sequencing platform for human genome analysis is developed.
escolifesciences.com1978Singapore$400M–
Manufacturer of biopharma equipment & IVF medical devices, and service provider for life science tools
agilent.com1995Santa Clara, United States–121
Diversified instruments are developed for scientific and laboratory management.
dayzerodiagnostics.com2016Boston, United States$48.6M48
Genome sequencing diagnostics for infectious diseases are developed.
unchainedlabs.com2015Pleasanton, United States$111M–
Multiplex protein stability platform for biologics is developed.
waters.com1958Milford, United States–9,341
Provider of laboratory management system for researchers and clinicians
Premium access

Detailed competitors of Cepheid

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of Cepheid

The website of Cepheid (cepheid.com) receives about 117.9K visits a month and ranks #496,659 among all websites worldwide, #489 in Biotechnology and Pharmaceuticals.

  • Monthly visits
    117.9K

    ▲ 71.4% vs previous month

  • Unique visitors
    31.5K

    per month

  • Global rank
    #496,659

    among all websites

  • Category rank
    #489

    Health · Biotechnology and Pharmaceuticals

Similar websites

Websites whose visitors overlap most with Cepheid. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
jobs-cepheid.icims.com
jobs-cepheid.icims.com
100%
–––
invernessmedical.com
invernessmedical.com
83%
–––
theravance.com
77%
4.4K#4,418,406View details
genomichealth.com
77%
1.9K#5,157,031View details
optimerpharma.com
77%
––View details
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
Premium access

All 40 similar websites and full traffic analytics for Cepheid

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 40 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Top companies in Genomics & Gene Therapy Platforms

10 companies that operate in the same segment as Cepheid (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
mRNA-based therapeutics for diseases including cancer and infections are developed.
2010Cambridge, Massachusetts, United StatesUSD 2.78 BUSD 1.94 B5,800
Digital sequencing technology for cancer detection is developed.
2012Redwood City, California, United StatesUSD 557.5 MUSD 982.02 M4,867
Circulating tumor DNA is screened for early cancer detection.
2016Menlo Park, California, United StatesUSD 2 BUSD 147.17 M1,141
Nanopore-based electronic systems for single-molecule analysis are developed.
2005Oxford, Oxfordshire, United KingdomUSD 1.34 BUSD 301.49 M1,372
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits
2006Sunnyvale, California, United StatesUSD 943.53 MUSD 189.9 M562
Provider of DNA testing services to create a family tree and ancestor
2003Yehud, Central District, IsraelUSD 40 M––
Genetically modified cell lines are developed using AAV gene-editing platform.
2007Cambridge, Cambridgeshire, United KingdomUSD 46.29 M––
Gene therapies for rare diseases including retinal dystrophies are developed.
2013Philadelphia, Pennsylvania, United StatesUSD 82.8 MUSD 64.73 M822
Therapeutics for genetic diseases are developed through targeted interventions.
2015Palo Alto, California, United StatesUSD 434.2 MUSD 502.08 M730
Provider of an online genealogy platform offering a host of services
1996Lehi, Utah, United StatesUSD 146.2 M––
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Cepheid

Premium access

Complete news archive for Cepheid

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Cepheid

Cepheid was founded in 1996 and raised its 1st funding round 4 years after it was founded.

Cepheid is headquartered in Sunnyvale, United States. It is registered at Sunnyvale, California, United States.

Cepheid is a funded company, having raised a total of $19.1M across 8 funding rounds to date. The company's 1st funding round was a Series C of $19.1M, raised on Jan 2000.

Cepheid has 208 employees.

The primary company behind Cepheid, Cepheid India Private Limited, reported revenue of ₹720 Cr for FY 2025, up 29% year on year.

Cepheid was founded in 1996 in Sunnyvale, United States, within the molecular diagnostics sector. Testing solutions are provided across categories including hospital-acquired infections, critical infectious diseases such as multi-drug resistant tuberculosis, influenza, respiratory syncytial virus, and enteroviral meningitis, as well as sexual health and genetic assessments like a 30-minute test for thrombosis risk. Operations focus on healthcare applications in the United States.

Cepheid's top competitors include Blackrock Neurotech, Agilent and Esco Lifesciences.

Cepheid has made 1 acquisition, including OncoMark.

Cepheid has 12 investors. Key investors include Medtronic, NIH, Danaher, HHS, and DARPA.

Cepheid operates through Cepheid India Private Limited.

Yes. Cepheid was acquired by Danaher in September 2016.

The legal entities of Cepheid currently have 3 directors, including Ganesh S Iyer, Santosh Kumar Nandi Duli, Dhiraj Sood.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available